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Multi-regional clinical trials have been widely used for efficient global new drug devel-
opments. Due to potential heterogeneity of patient populations, it is critical to evaluate
consistency of treatment effects across different regions in a multi-regional trial in order
to determine the applicability of the overall treatment effect to the patients in individual
regions. Quan et al. (2010) proposed definitions for the assessments of consistency of
treatment effects in multi-regional trials. To facilitate the application of their ideas to
design multi-regional trials, in this paper, we provide the corresponding R functions for
calculating the unconditional and conditional probabilities for demonstrating consistency
in relationship with the overall/regional sample sizes and the anticipated treatment ef-
fects. Detailed step by step instructions and trial examples are also provided to illustrate
the applications of these R functions.
Keywords: similarity, random effect, unconditional and conditional probabilities, interaction
test.
1. Introduction
The applications of multi-regional clinical trials (MRCT) in global new drug developments
present opportunities as well as challenges. One of the challenges is to assess consistency
of treatment effects across different regions in order to determine the applicability of the
overall treatment effect to the patients in individual regions. By consistency, we specifically
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refer to the similarity of treatment effects across regions. Some regulatory agencies (e.g.,
see Japanese guidance in Ministry of Health, Labour and Welfare of Japan 2007 for Joint
International Clinical Trials) recommend incorporating consistency assessment as a part of
the trial objective. To follow this recommendation, at the design stage, we have to first specify
a method or definition for consistency assessment and then derive the appropriate overall and
regional sample sizes to ensure desired probabilities for demonstrating consistency based on
the selected definition.
There could be many different ways to define consistency. Quan et al. (2010) explored a
number of consistency definitions. Due to space limitation, they only briefly presented the
formulas for calculating the unconditional and conditional probabilities for demonstrating
consistency. Nevertheless, they provided a lot of computation and simulation results to com-
pare these definitions under different parameter configurations. As they pointed out, many
factors can impact the probability for consistency assessment. To facilitate the application
of their ideas, in this paper, we provide source code of R (R Development Core Team 2011)
functions for the computations and simulations. Thus, MRCT designers can conveniently
perform explorations at the design stage to help them to determine trial specifications.
2. Definitions for consistency assessment
Let s be the number of regions in a MRCT and let Xij and Yij denote, respectively, the
control and experimental treatment group endpoint values for the jth patient within region i,
assumed to have normal distributions:
Xij ∼ N(µiX , σ2i ) and Yij ∼ N(µiY , σ2i ), for i = 1, . . . , s.
To simplify the presentation, at the design stage, we assume that within a region there are
equal numbers of patients in each treatment group, and we further assume that the variances
are the same across group and region, i.e., σ21 = · · · = σ2s = σ2. If this is not the case,
slight modifications in the following formulas and in the programs should be made before the




i=1Ni be the total number of patients in the trial in each treatment arm. Further,
let δi = µiY − µiX be the true treatment effect within region i, assuming that a larger value
implies a better outcome. We estimate δi by the sample mean difference between treatment
groups within region i:













Via Equation 1, the per group overall sample size that achieves 1 − β power to detect an






where za is the (1− a) quantile of the standard normal distribution.
Journal of Statistical Software – Code Snippets 3
Let fi denote the proportion of patients within region i, and ui the ratio of the treatment
effect in region i to the overall effect:
Ni/N = fi and δi/δ = ui.
Then
∑s
i=1 fi = 1 and
∑s
i=1 uifi = 1.
2.1. Definition 1: Exceeding a proportion of the observed overall effect
Definition 1 claims consistency when all observed region effects exceed some proportion of the
overall observed effect:
δ̂1 > πδ̂, δ̂2 > πδ̂, . . . , and δ̂s > πδ̂,
where π(≥ 0) is a quantity prespecified at the design stage.
The probability to claim consistency by Definition 1 is
P(δ̂i > πδ̂, 1 ≤ i ≤ s|δi, 1 ≤ i ≤ s)
= P(Zi > 0, 1 ≤ i ≤ s|δi, 1 ≤ i ≤ s),
where Zi = (1−πfi)δ̂i−π
∑
j 6=i fiδ̂j , 1 ≤ i ≤ s. We may be interested in assessing consistency
of treatment effects across regions only when the overall treatment effect is significant.
Given that there is an overall significant treatment effect, the conditional probability to claim
consistency by Definition 1 is
P(δ̂i > πδ̂, 1 ≤ i ≤ s|δ̂ − zασδ̂ > 0; δi, 1 ≤ i ≤ s)
=
P(Zi > 0, 1 ≤ i ≤ s;Zs+1 > 0|δi, 1 ≤ i ≤ s)






where Zi = (1−πfi)δ̂i−π
∑
j 6=i fiδ̂j , for 1 ≤ i ≤ s, Zs+1 = δ̂−zασ
√
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2.2. Definition 2: Exceeding a prespecified effect size
As an alternative to Definition 1, consider Definition 2:
δ̂1 > b, δ̂2 > b, . . . , and δ̂s > b,
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where b ≥ 0. A possible advantage of Definition 2 over Definition 1 is that if the overall
treatment effect is robust and the effects of certain regions are reasonable but not exceptional,
we may still be able to show consistency.




P(Zi > b|δi, i = 1, . . . , s)
and
P(Zi > b, 1 ≤ i ≤ s;Zs+1 > 0|δi, 1 ≤ i ≤ s)





respectively, where (Z1, Z2, . . . , Zs+1)
> is a multivariate normal random vector with mean
∆(π = 0) of Equation 2 and covariance matrix Σ(π = 0) of Equation 3.
2.3. Definition 3: Significantly exceeding a proportion of the overall effect
Definition 3 is in a hypothesis testing framework. The null and alternative hypotheses are
H30 : δ1 ≤ πδ or . . . or δs ≤ πδ versus H3a : δ1 > πδ and . . . and δs > πδ.
Consistency will be claimed if H30 is rejected and H
3
a is accepted.
Using a confidence interval approach, H30 will be rejected at significance level α
′ if







− 2π + π2) > 0, i = 1, . . . , s.
The unconditional and conditional probabilities of rejection are, respectively,
P(Z ′i > 0, 1 ≤ i ≤ s|δi, 1 ≤ i ≤ s)
and
P(Z ′i > 0, 1 ≤ i ≤ s;Zs+1 > 0|δi, 1 ≤ i ≤ s)






where Zs+1 is defined in Section 2.1.
2.4. Definition 4: Absence of significant treatment-by-region interaction
In Definition 4, applying the treatment by subgroup interaction test to MRCT with regions
as the subgroups, the null and alternative hypotheses are











follows a central chi-square distribution with (s− 1) degrees of freedom and consistency will
be claimed if H40 is not rejected. Since δ̂i − δ̂ and δ̂ are independent, the unconditional and
conditional probabilities of showing consistency based on Definition 4 are identical.
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2.5. Definition 5: Not significantly worse than the overall effect
Definition 5 is a modified version of Definition 4 in which we test the one-sided individual
hypotheses
H0i : δi ≥ δ versus Hai : δi < δ, i = 1, . . . , s.
If H0i is rejected and Hai is accepted at level α
′, the region i effect is not considered consistent
with the overall effect, and therefore consistency across all regions has not been shown. In
other words, in order to claim consistency, none of the H0i’s can be rejected; using a confidence
interval approach, the following must hold for all i:







− 1) > 0, i = 1, . . . , s.
Again, since δ̂i− δ̂ and δ̂ are independent, both the unconditional and conditional probabilities
of showing consistency based on Definition 5 are identical.
2.6. Other considerations: Random effect model
Hung (2007) considered the following model for a MRCT, in which region effect is considered
to be a random effect:
(δ̂i|δi) ∼ N(δi, 2σ2/Ni) and δi ∼ N(δ, τ2)
or unconditionally
δ̂i ∼ N(δ, τ2 + 2σ2/Ni).





where wi = 1/(τ
2 + 2σ2/Ni). For those definitions involving only the observed treatment
effects, like Definitions 1 and 2, the random effect model can be applied. For example, for
Definition 1, the conditional probability of showing consistency based on this random effect
model is
P(δ̂i > πδ̂
&, 1 ≤ i ≤ s|δ̂& > zασδ̂&)
=
P(Z&i > 0, 1 ≤ i ≤ s;Z&s+1 > 0)
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R function prob.def1 aims for calculating the unconditional and conditional probabilities to
claim consistency of treatment effect based on Definition 1.
R package mvtnorm (Genz et al. 2012; Genz and Bretz 2009) should be installed and loaded
first in order to use function pmvnorm. This function computes the cumulative distribution
function of the multivariate normal distribution with any covariance matrix:
R> library("mvtnorm")
The default input for prob.def1() is:
prob.def1(alpha = 0.025, beta = 0.2, delta = 0.25, s = 3, f = NULL,
u = NULL, pi = 1/3)
where:
 alpha: One-sided significance level for testing the overall treatment effect.
 beta: 1− β power for detecting an overall treatment effect of delta.
 delta: The standardized overall treatment effect for calculating the (1 − β) overall
power.
 s: Number of regions.
 f: Vector of (f1, f2, . . . , fs), where fi is the proportion of patients within region i and∑s
i=1 fi = 1.
 u: Vector of (u1, u2, . . . , us), where ui is the ratio of the treatment effect for region i to
the overall effect, ui = δi/δ, and
∑s
i=1 fiui = 1.
 pi: A threshold that each region should achieve at least pi of the observed overall effect
in order to claim consistency.
Then the program checks if the lengths of f and u are both equal to s,
∑s
i=1 fi = 1 and∑s
i=1 fiui = 1. If any of them is not true, the program will be stopped and a warning
message will be returned.
The returned values of prob.def1() are a list of
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 uncond.prob: unconditional probability to claim consistency.
 cond.prob: conditional probability to claim consistency given a significant overall treat-
ment effect.
The R functions for calculating the unconditional and conditional probabilities for claiming
consistency based on Definition 2–5 are prob.def2–prob.def5 respectively. They use similar
input arguments and provide similar returned values. Notice that unconditional and condi-
tional probabilities for Definitions 4 and 5 are identical. The prob.def4 could also be used
for power calculation for general subgroup analysis.
Definition 1 can be applied to the random effect models, and functions rand1.def1 and
rand2.def1 calculate the probabilities to claim consistency using δ̂& and δ̂ respectively.
Quan et al. (2010) also considered the minimum required proportion of sample size for a
particular region, say region 1, so that there is an (1-beta) probability of demonstrating
consistency. When there are 4 regions and the region effects are the same, the minimum
proportions of f ′1s under conditions f1 < f2 = f3 = f4, f1 = f2 < f3 = f4 and f1 = f2 = f3 <
f4 based on Definition x can be calculated by functions f11.defx, f12.defx and f13.defx
respectively (x = 1, 2, 3).
4. Examples
In this section, trial examples are used to illustrate the applications of the programs. Suppose
we want to conduct a MRCT in s = 3 regions. In order to have 80%(=1 − β) overall
power to detect an overall standardized treatment effect δ = 0.25 at one-sided significance
level α = 0.025, the overall sample size per treatment group should be N = 252. Let the
proportion vector of study patients in the 3 regions be f = (f1, f2, f3) = (1/3, 1/3, 1/3),
the ratio vector of the treatment effects to the overall treatment effect in the 3 regions be
u = (u1, u2, u3) = (1, 1, 1) and π = 1/s.
Then, the input parameters for prob.def1 are
R> alpha <- 0.025
R> beta <- 0.2
R> delta <- 0.25
R> s <- 3
R> pi <- 1/s
R> f <- c(1/3, 1/3, 1/3)
R> u <- c(1, 1, 1)
To make the exact replication of the outputs possible, we set the random number generator
seed using set.seed. Applying prob.def1 will yield
R> set.seed(5000)
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That is, the unconditional and conditional probabilities to claim consistency based on Def-
inition 1 for such a design setting are 67% and 76% respectively. If these probabilities are
considered too small, we can increase the overall power from 80% to 90% or decrease β from
0.2 to 0.1. Because of the increase in overall sample size from N = 252 to 337, the correspond-
ing unconditional and conditional probabilities are then 76% and 81% respectively. Basically,
we can adjust the overall sample size and f to reach the desired probability for consistency
assessment.
Consider the example in Quan et al. (2010). With 558 patients, 186 receiving placebo and
372 in the active treatment group, there was > 99% power to detect a between-treatment
difference of δ = 0.005 with σ = 0.013 for a significance level α = 0.025 one-sided test (to
have enough safety data to meet the regulatory requirement, this study was over powered
for efficacy analysis). At the design stage, we would like to determine the minimum required
proportion of sample size for a particular region, say Region 1, so that there was an 80%
probability of demonstrating consistency. If the sample sizes of the other 3 regions were the
same (f1 < f2 = f3 = f4) and conditional probability was the concern, then using Definition 1
with π = 1/4, f1 should be 13%. If the unconditional probability was set to 80%, f1 should
be 14%. These can be obtained by f11.def1 with specifications:
R> alpha <- 0.025
R> beta <- 0.01
R> delta <- 0.005
R> sigma <- 0.013
R> pi <- 1/4
R> u <- rep(1, 4)
R> set.pow <- 0.8





Notice that, when we run the program, if the desired probability for demonstrating consistency
is set to too high, the required minimum proportion f1 could be nonexistent, unless we increase
the overall sample size further.
5. Discussion
In the design stage of a MRCT, we are interested in the probability and the required propor-
tions of sample sizes of individual regions for claiming consistency of treatment effects. This
paper is developed to provide the R source codes for calculating probability and sample sizes
based on various definitions of consistency.
Functions prob.def1–prob.def5 calculate both the unconditional and conditional proba-
bilities for claiming consistency of treatment effect in MRCTs based on Definitions 1-5 of
Quan et al. (2010). For random effect model, Definition 1 is implemented in rand1.def1 and
rand2.def1 for two types of estimators of δ respectively. Definition 2 can also be applied
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to random effect model with slight modifications to functions rand1.def1 and rand2.def2.
The minimum required proportion of sample size for a particular region can be obtained by
functions f11.defx, f12.defx and f13.defx respectively for Definitions x = 1, 2, 3.
R function pmvnorm is used to compute the cumulative distribution function of the multivariate
normal distribution, which is included in R package mvtnorm of Genz et al. (2012). This
function produces probabilities for both the singular and nonsingular joint distributions.
As demonstrated in the trial examples in Section 4, program users have to adjust the overall
and regional sample sizes given the anticipated corresponding treatment effects to get the
desired probability. If the sample sizes for some regions are too small, these small regions
could be considered to be combined to form a new region. Otherwise, the probability will be
reduced dramatically. All these have to be prespecified in study protocol.
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